Senseonics (SENS) and Its Competitors Critical Contrast

Senseonics (NASDAQ:SENS – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its rivals? We will compare Senseonics to related companies based on the strength of its institutional ownership, risk, valuation, profitability, analyst recommendations, dividends and earnings.

Profitability

This table compares Senseonics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Senseonics -204.01% -186.11% -86.21%
Senseonics Competitors -191.42% -197.84% -21.82%

Analyst Ratings

This is a breakdown of recent recommendations for Senseonics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senseonics 1 3 3 0 2.29
Senseonics Competitors 4323 10552 18355 839 2.46

Senseonics currently has a consensus target price of $14.40, suggesting a potential upside of 68.76%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.14%. Given Senseonics’ higher possible upside, equities research analysts plainly believe Senseonics is more favorable than its rivals.

Insider & Institutional Ownership

12.4% of Senseonics shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 4.7% of Senseonics shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Senseonics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Senseonics $35.26 million -$69.11 million -3.71
Senseonics Competitors $1.90 billion $138.28 million 5.89

Senseonics’ rivals have higher revenue and earnings than Senseonics. Senseonics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Senseonics has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Senseonics’ rivals have a beta of 2.53, indicating that their average share price is 153% more volatile than the S&P 500.

Summary

Senseonics rivals beat Senseonics on 11 of the 13 factors compared.

Senseonics Company Profile

(Get Free Report)

Senseonics Holdings, Inc. develops continuous glucose monitoring (CGM) technology for people with diabetes. Its Eversense systems use a small sensor implanted under the skin to measure glucose levels, an external wearable transmitter to send readings, and a mobile app to display data and provide alerts. The company’s product line includes implantable CGM systems designed for extended wear, including the Eversense 365 system, which is designed to last up to one year. Unlike many CGM products that use sensors replaced more frequently, Eversense sensors are inserted and removed by a healthcare professional.

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.